Macrogenics, inc. (MGNX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Revenues:
Revenues

13,682

25,192

18,741

10,593

9,662

15,794

20,798

18,834

4,695

152,358

1,663

1,666

2,055

5,106

3,255

80,673

2,846

8,178

14,681

6,716

71,279

5,476

18,382

9,220

14,719

14,906

20,232

12,298

10,598

16,081

Costs and expenses:
Research and development

48,894

51,957

44,852

51,440

47,060

46,925

46,218

52,014

45,670

38,986

40,984

34,461

32,801

31,109

30,296

33,340

27,346

30,044

24,103

22,660

21,464

19,650

18,632

17,335

14,569

14,348

11,088

11,049

10,096

11,968

General and administrative

10,233

11,890

11,833

12,122

10,219

10,547

9,584

11,134

9,235

8,404

8,403

8,384

7,462

9,235

7,224

7,239

6,133

6,715

6,021

5,346

4,683

4,845

3,678

4,145

3,258

3,765

1,986

1,503

3,832

1,514

Total costs and expenses

59,127

63,847

56,685

63,562

57,279

57,472

55,802

63,148

54,905

47,390

49,387

42,845

40,263

40,344

37,520

40,579

33,479

36,759

30,124

28,006

26,147

24,495

22,310

21,480

17,827

18,113

13,074

12,552

13,929

13,482

Loss from operations

-45,445

-38,655

-37,944

-52,969

-47,617

-41,678

-35,004

-44,314

-50,210

104,968

-47,724

-41,179

-38,208

-35,238

-34,265

40,094

-30,633

-28,581

-15,443

-21,290

45,132

-19,019

-3,928

-12,260

-3,108

-3,206

7,158

-254

-3,331

2,598

Other income

721

8,259

-6,687

21,202

2,600

-2,966

975

1,070

674

758

681

525

553

455

419

370

270

130

1

-86

-3

1

0

1

0

1

-554

-40

-34

1

Net loss

-44,724

-30,396

-44,631

-31,767

-45,017

-44,644

-34,029

-43,244

-49,536

105,726

-47,043

-40,654

-37,655

-34,783

-33,846

40,464

-30,363

-28,451

-15,442

-21,376

45,129

-19,018

-3,928

-12,259

-3,108

-3,205

6,604

-294

-3,365

2,600

Other comprehensive income:
Unrealized gain on investments

56

-7

-11

34

3

-3

-18

40

39

-34

56

25

-26

-100

-41

7

57

-5

0

0

0

-

-

-

-

-

-

-

-

-

Comprehensive loss

-44,668

-30,403

-44,642

-31,733

-45,014

-44,647

-34,047

-43,204

-49,497

105,692

-46,987

-40,629

-37,681

-34,883

-33,887

40,471

-30,306

-28,456

-15,442

-21,376

45,129

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per common share (in usd per share)

-0.91

-0.61

-0.91

-0.65

-0.99

-1.01

-0.81

-1.03

-1.34

2.96

-1.28

-1.14

-1.08

-

-0.97

-

-0.88

-

-

-

-

-

-

-

-

-

-

-0.24

-2.93

-

Basic and diluted weighted average common shares outstanding (in shares)

49,012

48,976

48,902

48,845

45,606

42,371

42,239

42,153

36,936

36,857

36,779

35,784

34,958

-

34,766

-

34,503

-

-

-

-

-

-

-

-

-

-

1,219

1,148

-

Basic net income (loss) per common share (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.17

-

-

-0.46

-0.71

1.53

-

-0.14

-0.44

-0.12

-

0.14

-

-

0.00

Diluted net income (loss) per common share (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.12

-

-

-0.46

-0.71

1.42

-

-0.14

-0.44

-0.12

-

0.01

-

-

0.00

Basic weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34,616

-

-

33,339

30,059

29,415

-

27,751

27,651

26,262

-

1,184

-

-

1,092

Diluted weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36,017

-

-

33,339

30,059

31,684

-

27,751

27,651

26,262

-

21,242

-

-

21,502

Revenue From Collaborative Agreements
Revenues

12,967

24,556

17,984

9,987

9,497

14,974

20,617

18,552

4,501

152,081

1,076

1,081

1,278

4,178

2,014

78,497

1,893

7,924

14,681

5,598

71,165

5,378

18,283

9,202

14,401

14,737

20,111

11,838

10,066

15,532

Revenue From Government Agreements
Revenues

715

636

757

606

165

820

181

282

194

277

587

585

777

928

1,241

2,176

953

254

0

1,118

114

98

99

18

318

169

121

460

531

548